Task order 75N93024F00001 base award.
Active Awarded Last action
- Contract number
- 75N93024F00001
- Awardee
-
Allucent Government Services (Us) LLC UEI C7DJDL6EZT94
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,205,231
Award facts
- Contract value 100% obligated
- $3,205,231.00 Current and potential, with all options
- Completion date 80% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cary, NC 27513, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $3,143,983 | |
| Original award | $61,248 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Task Order 75N93024F00001 to Allucent Government Services (US) LLC on August 15, 2024, under the Early Phase Clinical Trial Units (EPCTU) indefinite delivery vehicle. This delivery order, with a ceiling value of $3.2 million and an ultimate completion date of May 14, 2027, will be performed in Cary, North Carolina. The contract utilizes a cost-plus-fixed-fee pricing structure with no set-aside designation. Allucent, formerly known as Pharm-Olam LLC, is a clinical research organization specializing in comprehensive services supporting clinical trials and medical countermeasure development for federal agencies, with demonstrated expertise across the entire clinical trial lifecycle and a particular focus on infectious disease research and public health preparedness.
This task order is issued under NIAID's $346.6 million multiple-award EPCTU program, which enables the conduct of Phase 0 through Phase III clinical trials for infectious disease products. Under this vehicle and parent contract, Allucent will leverage its core capabilities in clinical trial planning and execution, regulatory support, and specimen collection and management to advance NIAID's infectious disease research objectives. The company's selection reflects its established track record of delivering clinical trial services to HHS agencies, including significant prior awards from NIAID and the Office of the Assistant Secretary for Preparedness and Response.
Quick answers
Who was awarded contract 75N93024F00001?
75N93024F00001 was awarded to Allucent Government Services (Us) LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 15, 2024.
How much is contract 75N93024F00001 worth?
The government has obligated $3,205,231 on 75N93024F00001.
Is contract 75N93024F00001 an order under another contract?
Yes. 75N93024F00001 is a delivery order under 75N93022D00015, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93024F00001 competed?
The extent of competition for 75N93024F00001 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award